GlassScriptPhysician profile
Muhammad Ul Islam
NPI 1861752685
$2,481.37
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $252 · 2021: $467 · 2022: $952 · 2023: $621 · 2024: $21.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $414 · Food and Beverage: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $414.05 |
| Food and Beverage | $227.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $846.98 | 2022-2023 | Illumisite |
| Abbvie INC. | $478.21 | 2021-2024 | Vraylar, Mavyret |
| Gilead Sciences, INC. | $456.92 | 2019-2023 | |
| Lilly USA, LLC | $141.26 | 2019-2022 | |
| Novo Nordisk INC | $139.76 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.27 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.65 | 2019-2021 | |
| Glaxosmithkline, LLC. | $57.93 | 2020-2022 | |
| Mylan Specialty L.P. | $41.64 | 2019-2021 | |
| Adlon Therapeutics L.P. | $28.77 | 2020 | |
| Abbott Laboratories | $26.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.70 | 2022 | |
| Cranial Technologies, INC | $15.35 | 2021 | |
| Genentech USA, INC. | $15.02 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $12.62 | 2021 | |
| Merck Sharp & Dohme LLC | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ul Islam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.